Kaiying Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kaiying Yang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Jiangyuan Zhou
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China
4 shared publications - Tong Qiu
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China
4 shared publications - Xue Gong
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China
4 shared publications - Yi Ji
Division of Oncology, Department of Pediatric Surgery West China Hospital of Sichuan University Chengdu China
4 shared publications - Xuepeng Zhang
Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China
3 shared publications - Yuru Lan
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China
3 shared publications
Latest Publications
- 19 December 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1706-1710.e9
PPARγ promotes kaposiform hemangioendothelioma progression via the CD36-mediated lipid metabolic pathway
- 19 December 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1706-1710.e9
PPARγ promotes kaposiform hemangioendothelioma progression via the CD36-mediated lipid metabolic pathway
- Open Access
- 8 December 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (3) , 8073-8085
Clinical treatment, research topic, and global trends of Kaposiform hemangioendothelioma: a review and bibliometric analysis
Background: Kaposiform hemangioendothelioma (KHE) is an aggressive vascular tumor that primarily affects young children. This study aims to comprehensively analyze research trends and review current clinical treatments in KHE. Materials and methods: Publications related to KHE from 1993 to 2024 were retrieved from the Web of Science Core Collection database and analyzed bibliometrically using VOSviewer, CiteSpace, and the R package “bibliometrix.” Additionally, studies involving clinical treatment were further reviewed to analyze therapeutic efficacy and associated adverse events (AEs). Results: A total of 320 publications were included. An overall upward trajectory in annual publication counts was observed. The majority of top-cited papers originated from hospitals in the United States. Pediatric Dermatology was the most productive journal, and the most co-cited journal was the Journal of Pediatrics . The United States was the most collaborative, while China was the most productive. Sichuan University ranked as the top research institution, with Yi Ji from its affiliated West China Hospital having the highest H-index. Current research topics mainly focus on clinical characteristics and sirolimus treatment of KHE. Regarding the clinical treatments for KHE, sirolimus has emerged as the primary drug for KHE treatment due to its superior efficacy over other agents, with upper respiratory tract infections and oral mucositis being the most common AEs. Conclusion: This study is the first bibliometric analysis to provide a comprehensive overview of current research topics and trends in KHE. In addition, our results shows that sirolimus has emerged as the primary drug for KHE treatment.
- 8 December 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (3) , 8073-8085
Open AccessClinical treatment, research topic, and global trends of Kaposiform hemangioendothelioma: a review and bibliometric analysis
Background: Kaposiform hemangioendothelioma (KHE) is an aggressive vascular tumor that primarily affects young children. This study aims to comprehensively analyze research trends and review current clinical treatments in KHE. Materials and methods: Publications related to KHE from 1993 to 2024 were retrieved from the Web of Science Core Collection database and analyzed bibliometrically using VOSviewer, CiteSpace, and the R package “bibliometrix.” Additionally, studies involving clinical treatment were further reviewed to analyze therapeutic efficacy and associated adverse events (AEs). Results: A total of 320 publications were included. An overall upward trajectory in annual publication counts was observed. The majority of top-cited papers originated from hospitals in the United States. Pediatric Dermatology was the most productive journal, and the most co-cited journal was the Journal of Pediatrics . The United States was the most collaborative, while China was the most productive. Sichuan University ranked as the top research institution, with Yi Ji from its affiliated West China Hospital having the highest H-index. Current research topics mainly focus on clinical characteristics and sirolimus treatment of KHE. Regarding the clinical treatments for KHE, sirolimus has emerged as the primary drug for KHE treatment due to its superior efficacy over other agents, with upper respiratory tract infections and oral mucositis being the most common AEs. Conclusion: This study is the first bibliometric analysis to provide a comprehensive overview of current research topics and trends in KHE. In addition, our results shows that sirolimus has emerged as the primary drug for KHE treatment.
- Top Cited PapersOpen Access
- 21 August 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (10) , 1912-1927
TGF-β1 Promotes Angiogenesis via Endothelial-to-Mesenchymal Transition in Infantile Hemangioma
BACKGROUND: Infantile hemangioma (IH) is the most common benign tumor in infancy and severely affects aesthetics and function. Hemangioma-derived endothelial cells (HemECs) are the main cellular component of IH and contribute to angiogenesis in IH. TGF-β1 (transforming growth factor β1) can induce endothelial-to-mesenchymal transition (EndoMT). Few studies have investigated the role and mechanism of TGF-β1–mediated EndoMT in IH angiogenesis. METHODS: The expression of EndoMT markers in IH samples was evaluated via multiplexed immunofluorescence assay. Lentiviruses and small interfering RNA were used to regulate gene expression. Targeted lipidomic analysis was subsequently conducted. Protein interactions between TGF-β1 and potential effectors were examined. Biological changes in function were measured by migration, invasion, and tube formation in vitro and vessel formation in vivo. Autophagy-related structures were detected via transmission electron microscopy. BALB/C-nu mice were used for the hemangioma model. RESULTS: In this study, the active participation of EndoMT in proliferating IH was verified. TGF-β1 OE (TGF-β1 overexpression) induced EndoMT and promoted the migration, invasion, and angiogenic abilities of HemECs. In addition, TGF-β1 OE decreased the protein expression of CPT1A (carnitine palmitoyltransferase 1A). TGF-β1 treatment decreased the levels of L-palmitoylcarnitine (a downstream metabolite of CPT1A) in HemECs. Supplementation with L-palmitoylcarnitine partly reversed the functional changes caused by CPT1A KD (CPT1A knockdown). Furthermore, the effect of TGF-β1 OE +overexpression model of CPT1A was similar to that of CPT1A KD +L-palmitoylcarnitine in regulating the functional behaviors of HemECs. R(+) propranolol inhibited HemECs EndoMT and vessel formation in vivo. CONCLUSIONS: TGF-β1–mediated EndoMT promotes angiogenesis in IH. Targeting TGF-β1 could be a promising therapeutic strategy for inhibiting IH progression.
- 21 August 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (10) , 1912-1927
Top Cited PapersOpen AccessTGF-β1 Promotes Angiogenesis via Endothelial-to-Mesenchymal Transition in Infantile Hemangioma
BACKGROUND: Infantile hemangioma (IH) is the most common benign tumor in infancy and severely affects aesthetics and function. Hemangioma-derived endothelial cells (HemECs) are the main cellular component of IH and contribute to angiogenesis in IH. TGF-β1 (transforming growth factor β1) can induce endothelial-to-mesenchymal transition (EndoMT). Few studies have investigated the role and mechanism of TGF-β1–mediated EndoMT in IH angiogenesis. METHODS: The expression of EndoMT markers in IH samples was evaluated via multiplexed immunofluorescence assay. Lentiviruses and small interfering RNA were used to regulate gene expression. Targeted lipidomic analysis was subsequently conducted. Protein interactions between TGF-β1 and potential effectors were examined. Biological changes in function were measured by migration, invasion, and tube formation in vitro and vessel formation in vivo. Autophagy-related structures were detected via transmission electron microscopy. BALB/C-nu mice were used for the hemangioma model. RESULTS: In this study, the active participation of EndoMT in proliferating IH was verified. TGF-β1 OE (TGF-β1 overexpression) induced EndoMT and promoted the migration, invasion, and angiogenic abilities of HemECs. In addition, TGF-β1 OE decreased the protein expression of CPT1A (carnitine palmitoyltransferase 1A). TGF-β1 treatment decreased the levels of L-palmitoylcarnitine (a downstream metabolite of CPT1A) in HemECs. Supplementation with L-palmitoylcarnitine partly reversed the functional changes caused by CPT1A KD (CPT1A knockdown). Furthermore, the effect of TGF-β1 OE +overexpression model of CPT1A was similar to that of CPT1A KD +L-palmitoylcarnitine in regulating the functional behaviors of HemECs. R(+) propranolol inhibited HemECs EndoMT and vessel formation in vivo. CONCLUSIONS: TGF-β1–mediated EndoMT promotes angiogenesis in IH. Targeting TGF-β1 could be a promising therapeutic strategy for inhibiting IH progression.
- 11 November 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115922
Effects of propranolol on glucose metabolism in hemangioma-derived endothelial cells
- 11 November 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115922
Effects of propranolol on glucose metabolism in hemangioma-derived endothelial cells
- Open Access
- 25 June 2022
- Published by Springer Nature in Dermatology and Therapy
- Vol. 12 (7) , 1659-1670
Maternal and Perinatal Risk Factors for Infantile Hemangioma: A Matched Case-Control Study with a Large Sample Size
Introduction Infantile hemangioma (IH) is the most common benign tumor in infancy, but information about its pathogenesis is limited. The aim of this study was to determine maternal and perinatal risk factors for IH. Methods A total of 1033 IH patients were enrolled in the study between 2017 and 2020. IH patients were matched with controls by sex. Trained investigators collected detailed information from the participants. Logistic regression models were used for multivariate analysis. Results The statistical analysis demonstrated that miscarriage history (odds ratio [OR] = 4.275; 95% confidence interval [CI] [3.195, 5.720]), anemia in pregnancy (OR = 4.228; 95% CI [3.083, 5.799]), preterm premature rupture of membranes (PPROM) (OR = 3.182; 95% CI [1.359, 7.454]), placenta previa (OR = 2.440; 95% CI [1.787, 3.333]), threatened miscarriage (OR = 2.290; 95% CI [1.726, 3.039]), premature rupture of membranes (PROM) (OR = 1.785; P < 0.05), progesterone use (OR = 1.614; P < 0.001) and abnormal amniotic fluid volume (OR = 1.499; P < 0.05) were independent risk factors for IH. Gestational diabetes mellitus (GDM) (OR = 0.607; 95% CI [0.464, 0.794]), multiple gestations (OR = 0.407; 95% CI [0.232, 0.713]), hypothyroidism (OR = 0.407; 95% CI [0.227, 0.730]) and uterine fibroids (OR = 0.393; 95% CI [0.250, 0.618]) may reduce the risk of IH. Conclusions Maternal and perinatal factors are closely associated with IH occurrence. Our study provides reliable clues to guide further exploration of the pathogenesis of IH. Trial Registration ClinicalTrials.gov, NCT03331744. Plain Language Summary Infantile hemangioma is the most common benign tumor in children, which seriously affects appearance and function and even threatens life. The pathogenesis is not clear, a detailed case-control study of the maternal and perinatal periods with a large sample size will facilitate the development of individualized and precise treatment, early and timely interventions for high-risk children and improvement of prognosis. Our study found that miscarriage history, anemia in pregnancy, preterm premature rupture of membranes (PPROM), placenta previa, threatened miscarriage, premature rupture of membranes (PROM), progesterone use and abnormal amniotic fluid volume were independent risk factors for IH.
- 25 June 2022
- Published by Springer Nature in Dermatology and Therapy
- Vol. 12 (7) , 1659-1670
Open AccessMaternal and Perinatal Risk Factors for Infantile Hemangioma: A Matched Case-Control Study with a Large Sample Size
Introduction Infantile hemangioma (IH) is the most common benign tumor in infancy, but information about its pathogenesis is limited. The aim of this study was to determine maternal and perinatal risk factors for IH. Methods A total of 1033 IH patients were enrolled in the study between 2017 and 2020. IH patients were matched with controls by sex. Trained investigators collected detailed information from the participants. Logistic regression models were used for multivariate analysis. Results The statistical analysis demonstrated that miscarriage history (odds ratio [OR] = 4.275; 95% confidence interval [CI] [3.195, 5.720]), anemia in pregnancy (OR = 4.228; 95% CI [3.083, 5.799]), preterm premature rupture of membranes (PPROM) (OR = 3.182; 95% CI [1.359, 7.454]), placenta previa (OR = 2.440; 95% CI [1.787, 3.333]), threatened miscarriage (OR = 2.290; 95% CI [1.726, 3.039]), premature rupture of membranes (PROM) (OR = 1.785; P < 0.05), progesterone use (OR = 1.614; P < 0.001) and abnormal amniotic fluid volume (OR = 1.499; P < 0.05) were independent risk factors for IH. Gestational diabetes mellitus (GDM) (OR = 0.607; 95% CI [0.464, 0.794]), multiple gestations (OR = 0.407; 95% CI [0.232, 0.713]), hypothyroidism (OR = 0.407; 95% CI [0.227, 0.730]) and uterine fibroids (OR = 0.393; 95% CI [0.250, 0.618]) may reduce the risk of IH. Conclusions Maternal and perinatal factors are closely associated with IH occurrence. Our study provides reliable clues to guide further exploration of the pathogenesis of IH. Trial Registration ClinicalTrials.gov, NCT03331744. Plain Language Summary Infantile hemangioma is the most common benign tumor in children, which seriously affects appearance and function and even threatens life. The pathogenesis is not clear, a detailed case-control study of the maternal and perinatal periods with a large sample size will facilitate the development of individualized and precise treatment, early and timely interventions for high-risk children and improvement of prognosis. Our study found that miscarriage history, anemia in pregnancy, preterm premature rupture of membranes (PPROM), placenta previa, threatened miscarriage, premature rupture of membranes (PROM), progesterone use and abnormal amniotic fluid volume were independent risk factors for IH.